Notably, the IHC score of H3K9me2 in our cohorts is significantly higher in higher-grade and later-stage tumors compared to healthy tissue, lower-grade, earlier-stage, or less aggressive subtypes like luminal A. This observation suggests that H3K9me2 may play a more crucial role in the progression of more aggressive cancers or breast cancer that does not have hormone receptors. The gene discussed is NR4A1; the disease is breast cancer.